David Bredt, Chief Scientific Officer of Rapport Therapeutics ($RAPP), sold $2.16 million in company shares through 21 open market transactions over the past year. His latest sale took place on February 17, 2026. Among over 11,600 insiders with recent sales, Bredt ranks 3,343rd by total value, trailing the average of $8.6 million across 6.4 transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | M | Stock Options (Right to Buy) | 6000 | $0.00 | 88,080.0000 | 47,661,138 | 6.38% | 0.01% |
| Feb. 19, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | M | Common Stock | 6000 | $1.80 | 393,075.0000 | 47,661,138 | 1.55% | 0.01% |
| Feb. 17, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 2200 | $29.59 | 387,075.0000 | 47,661,138 | 0.57% | 0.00% |
| Feb. 17, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 5400 | $28.95 | 389,275.0000 | 47,661,138 | 1.37% | 0.01% |
| Feb. 17, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 900 | $28.02 | 394,675.0000 | 47,661,138 | 0.23% | 0.00% |
| Feb. 2, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | A | Stock Option (Right to Buy) | 103000 | $0.00 | 103,000.0000 | 47,661,138 | 9999.99% | 0.22% |
| Jan. 15, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 200 | $27.40 | 395,575.0000 | 47,661,138 | 0.05% | 0.00% |
| Jan. 15, 2026 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8300 | $26.83 | 395,775.0000 | 47,661,138 | 2.05% | 0.02% |
| Dec. 31, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 6567 | $30.05 | 404,075.0000 | 47,661,138 | 1.60% | 0.01% |
| Dec. 31, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | A | Common Stock | 18000 | $0.00 | 410,642.0000 | 47,661,138 | 4.20% | 0.04% |
| Dec. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 796 | $30.68 | 392,642.0000 | 47,661,138 | 0.20% | 0.00% |
| Dec. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 7704 | $29.95 | 393,438.0000 | 47,661,138 | 1.92% | 0.02% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 3156 | $24.84 | 406,486.0000 | 47,661,138 | 0.77% | 0.01% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 5344 | $25.39 | 401,142.0000 | 47,661,138 | 1.31% | 0.01% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 1082 | $26.16 | 409,642.0000 | 36,496,437 | 0.26% | 0.00% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 7418 | $25.73 | 410,724.0000 | 36,496,437 | 1.77% | 0.02% |
| Sept. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 5098 | $23.88 | 421,544.0000 | 36,496,437 | 1.19% | 0.01% |
| Sept. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 3402 | $24.66 | 418,142.0000 | 36,496,437 | 0.81% | 0.01% |
| Aug. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 200 | $15.79 | 426,642.0000 | 36,496,437 | 0.05% | 0.00% |
| Aug. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8300 | $14.98 | 426,842.0000 | 36,496,437 | 1.91% | 0.02% |
| July 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8500 | $14.00 | 435,142.0000 | 36,496,437 | 1.92% | 0.02% |
| June 16, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8500 | $11.00 | 443,642.0000 | 36,496,437 | 1.88% | 0.02% |
| May 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8500 | $9.56 | 452,142.0000 | 36,496,437 | 1.85% | 0.02% |
| April 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8500 | $9.57 | 460,642.0000 | 36,496,437 | 1.81% | 0.02% |
| March 14, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | S | Common Stock | 8500 | $10.85 | 469,142.0000 | 36,496,437 | 1.78% | 0.02% |
| Feb. 3, 2025 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2024 | Rapport Therapeutics, Inc. | $RAPP | Bredt David | Chief Scientific Officer | A | Stock Option (Right to Buy) | 28302 | $0.00 | 28,302.0000 | 0 | 9999.99% | 0.00% |